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donor cells in blood vessels throughout the heart (63% of total cells
enumerated). Rarer donor cells were also found through the myo-
cardium in cells with patterns exhibiting the cross-striations of
striated muscle. Donor cells stained positive for Troponin I-C
(speciﬁc for cardiac muscle Troponin I) and for myosin heavy
chain (1-2 cells per 10-20 high power ﬁelds). Conclusion: We
documented engraftment and differentiation of donor UCB cells
into cardiac myocytes in a child transplanted for MPS III. It is
possible that donor cells may selectively homed to damaged myo-
cardium and subsequently differentiated in situ. After engraftment,
differentiation into myocardial cells may improve cardiac function
and subsequently diminish the likelihood of progressive heart fail-
ure with its attendant morbidity and mortality in patients with
MPS syndromes.
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LOWER POST-TRANSPLANT SERUM ALBUMIN LEVELS PREDICT SIG-
NIFICANTLY POORER SURVIVAL AFTER ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Pedicano, J., Verma, A., Tomblyn, M., Gordon, L., Singhal, S., Tall-
man, M., Williams, S., Winter, J., Mehta, J. Northwestern University,
Chicago
Low serum albumin is a non-speciﬁc but powerful indicator of
poorer outcome in elderly and hospitalized patients, after surgery,
and in several other circumstances including on routine testing
(Goldwasser Feldman, J Clin Epidemiol 1997;50:693-703). Based
upon the observation that patients with signiﬁcant complications
after transplantation usually have lower albumin levels and those
with higher albumin levels are usually well, we analyzed the rela-
tionship between post-transplant albumin levels and overall sur-
vival in recipients of non-myeloablative allogeneic transplantation
(NMAT). Overall survival (OS) was chosen as an endpoint rather
than disease-free survival because a number of patients relapsing
after NMAT attain remission again and survive long-term, and a
higher albumin level after relapse may be a predictor of better
outcome too. 47 consecutive NMAT recipients with hematologic
malignancies (27-66 years; median 51) were studied. The condi-
tioning regimen was 100 mg/m2 melphalan on day -1 ( 50 mg/kg
cyclophosphamide on day -2 if no prior autograft), cyclosporine
(HLA-matched sibling donor; n  32) or tacrolimus (1-locus
mismatched sibling donor; n 3, or unrelated donor; n 12), and
mycophenolate mofetil. Albumin levels on days 0, 30, 60 and 90,
and average albumin levels over weeks 1-2, 3-4, 5-6, 7-8, 9-10,
11-12, and 13-16 were analyzed. All comparisons were for 3 vs
3 g/dL except weeks 1-2 and 3-4 where a 2.5 vs 2.5 g/dL
cut-off was used because most patients had relatively low albumin
levels for the ﬁrst month. In each of the 11 comparisons, the group
with the lower albumin level had a lower probability of OS at 18
months. The table shows the OS differences were statistically
signiﬁcant. This analysis conﬁrms our clinical impression of the
poor prognostic implication of low albumin levels after allogeneic
transplantation. Further work is required to explore how the out-
come of patients with low albumin can be improved by modifying
medical management.
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TEMPO OF NEUTROPHIL RECOVERY AND THE DEFINITION OF MY-
ELOID ENGRAFTMENT AFTER ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION (HSCT) IN PATIENTS NOT RECEIVING
GROWTH FACTORS POST-TRANSPLANT
Naik, P., Verma, A., Pedicano, J., Gordon, L., Singhal, S., Tallman,
M., Williams, S., Winter, J., Mehta, J. Northwestern University,
Chicago
Time to myeloid recovery after HSCT is usually deﬁned as the
ﬁrst of 3 consecutive days with an absolute neutrophil count (ANC)
of 0.5 109/L. HSCT registries and FACT require ANC0.5 for
3 days as adequate evidence of engraftment. The ﬁrst day with
ANC 0.5 can be considered the day of engraftment in autograft
recipients (Bone Marrow Transplant 2002;30:749-752). We have
shown this in 78 allograft recipients too (Rihn et al. ASH 2002).
However, the allograft study was limited by the fact that most
patients had received G-CSF post-transplant, and the stem cell
source was not uniform. We have now studied 49 patients al-
lografted using blood stem cells who did not receive post-trans-
plant G-CSF to see if the tempo of myeloid recovery was sustained.
The conditioning regimen, 100 mg/m2 melphalan ( 50 mg/kg
cyclophosphamide if no prior autograft), induced severe neutrope-
nia (ANC 0.1) in all patients. The CD34 cell dose was 1.4-
11.8  106/kg (median 5.0). The time to ANC 0.5 was 10-23
days (median 13). Potentially acceptable evidence of engraftment,
ANC on the 2 days following an initial value of 0.5, was available
in 46 (94%). The remaining 3 patients had ANC 0.5 for the ﬁrst
and second days but died after that (n  2) or did not have a
differential count available (n  1). ANC increased from day 1 to
2 in 41 of 46 patients, and declined in 5 (0.5 in 2, 0.5 in 3. 2 of
the latter had ANC 0.5 the next day). ANC increased from day
2 to 3 in 44 of 46 patients, and declined in 2 (0.5 in both). ANC
increased from day 1 to 3 in 45 of 46 patients; declining below 0.5
in 1 patient. Thus, in 43 of 46 patients, the ﬁrst day with ANC 0.5
was also the ﬁrst of 3 consecutive days with ANC 0.5. These data
support our previous observations that in the majority of al-
lografted patients, ANC does not decline signiﬁcantly immediately
after recovering to0.5 whether or not myeloid growth factors are
administered post-transplant. Therefore, it is not essential to ob-
tain WBC counts on 3 consecutive days to deﬁne myeloid engraft-
ment. The ﬁrst day with ANC 0.5 should be considered the day
of myeloid engraftment in allograft as well as autograft recipients.
This simple change in deﬁnition and practice has signiﬁcant po-
tential impact on convenience (unnecessary clinic visits for pa-
tients; particularly out-patient mini-allografts), cost (blood counts,
home health visits, ancillary charges), and compliance (acceptable
deﬁnition of engraftment by HSCT registries and FACT).
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INTERACTION BETWEEN DONOR TYPE AND CMV SEROSTATUS ON
MORTALITY AFTER ALLOGENEIC HSCT: DO PREEMPTIVE APPROACHES
WORK EQUALLY FOR ALL?
Nichols, W.G., Gooley, T.A., Boeckh, M. Fred Hutchinson Cancer
Research Center, Seattle, WA
Background: In the current era of effective preemptive antiviral
approaches, cytomegalovirus (CMV) is now a rare cause of early
mortality after hematopoietic stem cell transplantation (HSCT).
Though the direct effects of CMV (such as CMV pneumonia) have
been largely eliminated, many recent cohort studies (reviewed in
Table.
Time
Higher Albumin Lower Albumin
Pn 1-y OS (95% CI) (%) n 1-y OS (95% CI) (%)
Day 60 25 73 (51-94) 13 48 (19-78) 0.01
Weeks 1-2 24 75 (56-94) 23 20 (0-51) 0.01
Weeks 3-4 24 76 (56-97) 22 35 (9-61) 0.01
Weeks 5-6 27 69 (48-90) 17 42 (17-67) 0.02
Weeks 7-8 24 78 (58-97) 14 33 (5-62) 0.003
Weeks 9-10 24 74 (54-94) 11 47 (14-79) 0.05
Table.
Day 1 Day 2 Day 3
ANC (109/L) 0.74 (0.53-2.10) 1.43 (0.36-10.94) 2.46 (0.44-30.74)
Change from
Day 1 (%) 67 (36 to 574) 176 (21 to 1793)
Change from
Day 2 (%) 50 (17 to 1925)
ANC <0.5
(n) 0 3 (7%) 1 (2%)
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Boeckh M, Nichols WG et al, BBMT 2003) have demonstrated
that at least some CMV seropositive transplant recipients appear to
have a persistent mortality disadvantage when compared to their
seronegative counterparts. The speciﬁc transplant characteristics
that underlie this relationship remain unclear, but most studies
have focused on the impact of serostatus on mortality after T-cell
depleted transplantation. We tested the hypothesis that CMV
serostatus inﬂuences mortality among recipients of T-cell-replete
transplants from mismatched or unrelated donors (MM/URD, n
1001) but not matched sibling donors (MSD, n  749) in the
preemptive era. Methods: The impact of CMV serostatus ( or
) of the donor (D) and recipient (R) on overall mortality was
assessed among 1750 consecutive allogeneic HSCT recipients at
our center by means of multivariable regression models. Support-
ive care for this cohort included preemptive ganciclovir, which was
applied for any level of pp65 antigenemia and continued until day
100 after transplant. Results: Among recipients of transplants
from matched sibling donors, overall mortality among R and
D/R-patients was comparable to that of D-/R-patients after
adjusting for patient/donor age, underlying disease and disease-
speciﬁc risk, conditioning regimen, cell source, GVHD prophy-
laxis, cell dose, and year of transplant (Table). Overall mortality
was signiﬁcantly higher, however, among both seropositive recip-
ients and D/R-patients when compared to D-/R-patients in the
setting of mismatched sibling or unrelated donor (MM/URD)
transplantation. Formal tests for interaction according to donor
type yielded suggestive trends for the D-/R and D/R-groups
(p  0.13 and 0.16, respectively). Conclusions: Preemptive strat-
egies appear to be effective for recipients of MSD HSCT, yet fail
to eliminate the mortality associated with CMV seropositivity
among recipients of mismatched or unrelated donor transplants.
New drugs and new approaches (including possible re-examination
of antiviral prophylaxis) are clearly needed for these high-risk
patients.
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SOURCE OF DONOR STEM CELLS IMPACTS INCIDENCE OF BLEEDING
AND PLATELET AND RBC TRANSFUSION REQUIREMENTS DURING
STEM CELL TRANSPLANTATION (SCT): RESULTS OF THE PHASE III
SPRINT TRIAL OF INTERCEPT PATHOGEN INACTIVATED PLATELETS
Vesole, D.1, Stadtmauer, E.2, Goodnough, L.T.3, Coutre, S.4, Howard,
F.5, Lin, J.-S.6, Conlan, M.G.6, for the SPRINT Study Group 1. Med
College WI, Milwaukee, WI; 2. Univ of PA Health System, Philadel-
phia, PA; 3. Washington Univ Sch Med., St. Louis, MO; 4. Stanford
Univ Sch Med, Stanford, CA; 5. Loma Linda Univ Cancer Inst., Loma
Linda, CA; 6. Cerus Corporation, Concord, CA
Background: INTERCEPT Platelets (IP) are prepared with
Helinx® technology (amotosalen HCl and UVA) to inactivate a
broad range of viruses, bacteria, and protozoa, as well as WBCs
which can cause transfusion reactions and TA-GVHD. Methods:
A double-blind, parallel group Phase III trial (SPRINT) random-
ized patients (pts) with malignancy undergoing chemotherapy only
(CTX) (19%) or SCT (78%) to treatment with IP or Reference
(RP) platelet (plt) transfusions (tx) for up to 28 days. The prophy-
lactic tx threshold, selected by the treating physician, was
10109/L in 61% and 20109/L in 26% of pts. Results: 645 pts
were tx’ed (318 IP vs 327 RP). The primary endpoint, equivalence
of IP to RP in the control of moderate and severe (WHO Grade 2
and higher) bleeding, was demonstrated. Diagnosis (dx) and anti-
neoplastic regimen (SCT vs CTX) were well balanced between IP
and RP. 65% of SCT were autologous (auto) and 35% were
allogeneic (allo); 70% were peripheral blood (PB) and 26% bone
marrow (BM). 86% of PBSCT and 18% of BMT were auto. There
were signiﬁcant differences in dx, plt tx threshold, duration of plt
support, no. of plt and RBC tx, and incidence and duration of
Grade 2 or higher bleeding among auto SCT, allo SCT, and CTX
pts (all p-values  0.01). Leukemia was more common in allo than
auto SCT; lymphoma, plasma cell dyscrasia, and solid tumor were
more common in auto than allo SCT; acute leukemia was the most
common dx for CTX pts (p  0.001). Pts receiving auto SCT had
the lowest tx threshold, shortest duration of plt support, fewest plt
and RBC tx, and the lowest incidence and duration of Grade 2 or
higher bleeding. Allo SCT were on the other extreme, and CTX
pts were intermediate. No difference in incidence or duration of
bleeding was observed between IP and RP for SCT pts. Conclu-
sions: Allo SCT was associated with a longer duration of plt
support, more plt and RBC tx, and a higher incidence and duration
of signiﬁcant bleeding than auto SCT or CTX. INTERCEPT
Platelets were as effective as Reference platelets in control of
Grade 2 and higher bleeding regardless of dx, anti-neoplastic tx, or
stem cell source.
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LONG-TERM, APHERESIS/HEMODIALYSIS CATHETERS DECREASE THE
INCIDENCE OF CATHETER-RELATED BLOOD STREAM INFECTIONS (CR-
BSI) AND VENOUS THROMBOSIS (VT) IN PATIENTS WITH AL AMYLOID-
OSIS (ALA) UNDERGOING HIGH-DOSE MELPHALAN AND AUTOLOGOUS
STEM CELL TRANSPLANT (AUSCT)
Finn, K., Sanchorawala, V., Seldin, D., Kunz, R., Quillen, K. Boston
Medical Center, Boston, MA
Reported catheter-related complications (CRC) during AuSCT
include blood stream infections (BSI), non-patent catheters, cath-
eter site bleeding and VT. ALA patients with nephrotic syndrome
have a greater risk of infection and VT. We performed a retro-
spective review of CRC in 196 ALA patients receiving either a 12
fr non-tunneled catheter (NTC) or a 14 fr tunneled/cuffed cath-
eter (TC). Catheters were intended to be used from stem cell
collection through chemotherapy and re-engraftment, were in-
serted by interventional radiology, and were cared for with the
same catheter care regimen. The majority of the NTC’s (n  103)
were inserted on the left side and the TC (n 93) were inserted on
the right side. The NTC group had 6 CR-BSI and 5 VT, and the
TC group had none. Line patency problems occurred in the NTC
group but not with TC: they were resolved in the NTC group after
the catheter instillation policy was changed from a heparin diluted
with saline solution to approximately 3000U/cc to an undiluted
heparin concentration of 5000U/cc. Bleeding around the catheter
Table. CMV Serostatus and Mortality after HSCT
Donor/Recipient
CMV Serostatus
Hazard Ratio for Mortality
(95% CI)
MSD
(n  749)
MM/URD
(n  1001)
D/R (n  628) 1.0 (ref) 1.0 (ref)
D/R (n  467) 1.07 (0.81-1.42) 1.26 (1.01-1.58)
D/R (n  393) 0.90 (0.65-1.24) 1.29 (1.04-1.60)
D/R (n  262) 0.98 (0.70-1.38) 1.36 (1.06-1.74)
Abbreviations: MSD, matched sibling donor; MM/URD, mis-
matched or unrelated donor.
Table. Study Endpoints for SCT Patients
Endpoint
Auto SCT Allo SCT
IP
(N  154)
RP
(N  171)
P
Value
IP
(N  86)
RP
(N  91)
P
Value
Plt tx threshold
10 109/L (%) 70 68 0.29 48 46 0.82
Grade 2
bleeding
(% pts) 46 51 0.44 73 74 1.00
Grade 3/4
bleeding
(% pts) 0 2 0.25 9 10 1.00
Days of Grade 2
bleeding 1.9 1.4 0.10 5.0 4.9 0.83
Duration plt
support (d) 8.8 7.2 0.05 16.8 16.7 0.88
No. plt tx 5.7 3.7 <0.01 14.0 11.3 0.07
No. RBC tx 3.4 2.7 0.04 6.1 6.6 0.58
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